Insurance coverage gaps impact patients with rare cancers

Insurance coverage for rare cancer treatments is frequently lagging behind advancements in genomic science and precision medicine. This gap is highlighted by the case of Mason Henderson, a 21-year-old from Texas who died following a battle with an extremely rare brain tumor that the World Health Organization only named in 2021.

Despite medical specialists recommending the drug Lynparza, manufactured by Merck and AstraZeneca, Henderson’s insurer refused to cover the treatment because there were no established clinical guidelines for his specific condition. His mother, Tabitha Lowe, noted that the lack of coverage felt like discrimination based on the rarity of the disease.

Approximately one-quarter of all cancer patients in the United States are diagnosed with tumors considered rare. While molecular testing can identify potential effective medicines, insurers typically rely on FDA-approved labels and standard clinical guidelines, which often do not exist for rare afflictions. This creates a systemic barrier where scientific evidence for targeted therapies may exist, but reimbursement is denied due to a lack of formal regulatory precedents.